Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib

Philippe A. Cassier; Armelle Dufresne; Samia Arifi; Hiba Sayadi; Isabelle Ray-Coquard; Pierre Paul Bringuier; Jean Yves Scoazec; Laurent Alberti; Jean Yves Blay

doi:10.1007/s11894-008-0102-z

Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib

Philippe A. Cassier, Armelle Dufresne, Samia Arifi, Hiba Sayadi, Isabelle Ray-Coquard, Pierre Paul Bringuier, Jean Yves Scoazec, Laurent Alberti, Jean Yves Blay

Research output: Contribution to journal › Review article › peer-review

9 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GIST) are rare tumors of mesenchymal origin that may arise anywhere along the gastrointestinal tract or in the peritoneum. In most cases, GIST harbor mutations of KIT or PDGFRA. Imatinib mesylate (IM), a small-molecule tyrosine kinase inhibitor developed for the treatment of chronic myeloid leukemia, has been shown to be active against these mutations and has significant activity in patients with metastatic GIST. However, resistance to IM emerges after a median of 24 months of treatment. Sunitinib malate (SU) has been approved for the treatment of patients with IM-resistant advanced GIST, but the median progression-free survival in this setting is only 6 months. This article reviews the current knowledge regarding IM and SU resistance in GIST, as well as the available options for the management of GIST resistant to IM and SU.

Original language	English
Pages (from-to)	555-561
Number of pages	7
Journal	Current Gastroenterology Reports
Volume	10
Issue number	6
DOIs	https://doi.org/10.1007/s11894-008-0102-z
Publication status	Published - 1 Dec 2008
Externally published	Yes

Access to Document

10.1007/s11894-008-0102-z

Cite this

@article{127e54555da947b1954c9380e02201c5,

title = "Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib",

abstract = "Gastrointestinal stromal tumors (GIST) are rare tumors of mesenchymal origin that may arise anywhere along the gastrointestinal tract or in the peritoneum. In most cases, GIST harbor mutations of KIT or PDGFRA. Imatinib mesylate (IM), a small-molecule tyrosine kinase inhibitor developed for the treatment of chronic myeloid leukemia, has been shown to be active against these mutations and has significant activity in patients with metastatic GIST. However, resistance to IM emerges after a median of 24 months of treatment. Sunitinib malate (SU) has been approved for the treatment of patients with IM-resistant advanced GIST, but the median progression-free survival in this setting is only 6 months. This article reviews the current knowledge regarding IM and SU resistance in GIST, as well as the available options for the management of GIST resistant to IM and SU.",

author = "Cassier, {Philippe A.} and Armelle Dufresne and Samia Arifi and Hiba Sayadi and Isabelle Ray-Coquard and Bringuier, {Pierre Paul} and Scoazec, {Jean Yves} and Laurent Alberti and Blay, {Jean Yves}",

year = "2008",

month = dec,

day = "1",

doi = "10.1007/s11894-008-0102-z",

language = "English",

volume = "10",

pages = "555--561",

journal = "Current Gastroenterology Reports",

issn = "1522-8037",

number = "6",

}

TY - JOUR

T1 - Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib

AU - Cassier, Philippe A.

AU - Dufresne, Armelle

AU - Arifi, Samia

AU - Sayadi, Hiba

AU - Ray-Coquard, Isabelle

AU - Bringuier, Pierre Paul

AU - Scoazec, Jean Yves

AU - Alberti, Laurent

AU - Blay, Jean Yves

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Gastrointestinal stromal tumors (GIST) are rare tumors of mesenchymal origin that may arise anywhere along the gastrointestinal tract or in the peritoneum. In most cases, GIST harbor mutations of KIT or PDGFRA. Imatinib mesylate (IM), a small-molecule tyrosine kinase inhibitor developed for the treatment of chronic myeloid leukemia, has been shown to be active against these mutations and has significant activity in patients with metastatic GIST. However, resistance to IM emerges after a median of 24 months of treatment. Sunitinib malate (SU) has been approved for the treatment of patients with IM-resistant advanced GIST, but the median progression-free survival in this setting is only 6 months. This article reviews the current knowledge regarding IM and SU resistance in GIST, as well as the available options for the management of GIST resistant to IM and SU.

AB - Gastrointestinal stromal tumors (GIST) are rare tumors of mesenchymal origin that may arise anywhere along the gastrointestinal tract or in the peritoneum. In most cases, GIST harbor mutations of KIT or PDGFRA. Imatinib mesylate (IM), a small-molecule tyrosine kinase inhibitor developed for the treatment of chronic myeloid leukemia, has been shown to be active against these mutations and has significant activity in patients with metastatic GIST. However, resistance to IM emerges after a median of 24 months of treatment. Sunitinib malate (SU) has been approved for the treatment of patients with IM-resistant advanced GIST, but the median progression-free survival in this setting is only 6 months. This article reviews the current knowledge regarding IM and SU resistance in GIST, as well as the available options for the management of GIST resistant to IM and SU.

UR - http://www.scopus.com/inward/record.url?scp=60749129979&partnerID=8YFLogxK

U2 - 10.1007/s11894-008-0102-z

DO - 10.1007/s11894-008-0102-z

M3 - Review article

C2 - 19006610

AN - SCOPUS:60749129979

SN - 1522-8037

VL - 10

SP - 555

EP - 561

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

IS - 6

ER -

Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib

Abstract

Access to Document

Other files and links

Cite this